Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

HOUSTON, June 25, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced a presentation at the American Association of Cancer Research (AACR) Annual Meeting held from June 22nd-24th, 2020, illustrating a unique approach to creating drugs capable of reaching tumors hiding in organs where existing anticancer drugs cannot accumulate in therapeutic concentrations. A poster presentation entitled, “Targeting Cancer Sanctuary Sites: A Novel Approach to the Treatment of Lung Localized Tumors,” provided an overview of data demonstrating that uniquely high uptake and retention of Annamycin in the lungs results in consistently high in vivo activity against wide range of lung-localized tumors in mice.

The release as fetched from its publisher. moleculin.com ↗